Isolation and Mutagenesis of Streptokinase Producing Bacteria by Thaer T. A.  Abdelghani et al.
American Journal of Immunology 1 (4): 125-129, 2005 
ISSN 1553-6203 
© 2005 Science Publications 
Corresponding Author:  Dr. Adinarayana Kunamneni, Department of Pharmaceutical Sciences, Andhra University, India, Tel: 
+91 891 2505519, Fax: ++91 891 2755547  
 
125 
 
Isolation and Mutagenesis of Streptokinase Producing Bacteria 
 
Thaer Taleb Abed Abdelghani, Adinarayana Kunamneni, Poluri Ellaiah 
Pharmaceutical Biotechnology Division, Department of Pharmaceutical Sciences  
Andhra University, Visakhapatnam – 530 003, India. 
 
Abstract: Of 103 b-haemolytic Streptococci (with haemolytic activity) in total were isolated from 
different samples of blood and biomass from infected throat, 47 isolates exhibited streptokinase (SK) 
activity.  T3, identified as a new variant of Streptococcus equisimilis, was found to be excellent SK 
producer in submerged fermentation and was selected for strain improvement studies. This strain was 
mutagenized by UV and N-methyl-N’-nitro-N-nitroso guanidine (NTG). The isolation of mutants and 
the SK activity of selected mutants were described. The SK yield of the best UV mutant AUV10 was 
120% higher than the wild strain (T3). Also, the SK yield of the best NTG mutant NUV7 was 146% 
higher than the wild strain (T3). The results indicated that UV and NTG were effective mutagenic 
agents for strain improvement of S. equisimilis T3 for enhanced SK productivity.  
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INTRODUCTION 
 
A  blood  clot  (thrombus)  developed  in  the 
circulatory system can cause vascular blockage leading 
to  serious  consequences  including  death.  A  healthy 
hemostatic system suppresses the development of blood 
clots in normal circulation, but reacts extensively in the 
event  of  vascular  injury  to  prevent  blood  loss. 
Outcomes  of  a  failed  hemostasis  include  stroke, 
pulmonary embolism, deep vain thrombosis and acute 
myocardial  infraction.  Pathologies  involving  a  failure 
of  hemostasis  and  the  development  of  clot  require 
clinical  intervention  consisting  of  intravenous 
administration  of  thrombolytic  agents  (Collen  et  al., 
1988,  Collen,  1990  and  Francis  and  Marder,  1991; 
Banerjee et al., 2004). Streptokinase is one such agent. 
Other  thrombolytic  or  fibrinolytic  agents  include 
urokinase  and  the  tissue  type  plasminogen  activator 
(tPA).  
Numerous trails have been conducted to compare 
the  clinical  efficacy  of  recombinant  tPA  and 
streptokinase. Generally, these investigations have not 
revealed  a  clear  preference  for  either  drug. 
Streptokinase  is  as  effective  as  recombinant  tPA  in 
treating  acute  myocardial  infarction  (Sherry  and 
Marder, 1991), and it is certainly more cost-effective; 
however,  its  use  is  not  risk  free.  In  view  of  the 
relatively  recent  availability  of  the  competing 
recombinant tPA, skepticism is being expressed about 
the continued viability of streptokinase therapy (Sane 
and Little, 1998 and Werf, 1999). Despite this, research 
on  streptokinase  continues,  and  it  remains  a  vital 
affordable  therapy  especially  in  the  world's  poorer 
healthcare systems. 
Streptokinase  (SK)  is  an  extracellular  protein 
produced by many strains of b- haemolytic streptococci 
(Tillet and Garner, 1933). It facilitates lyses of blood 
clots by activating the plasminogen, to the fibrinolytic 
enzyme, plasmin.  The SK has been currently used in 
clinical medicine as a therapeutic agent in the treatment 
of  acute  myocardial  infraction  following  coronary 
thrombosis (Ko et al., 1995; Banerjee et al., 2004).  
The SK has been reported that Feldman (1974), 
increase in yield of the SK with strain H-46A.  Malke 
and  Ferretti  (1984)  used  brain-heart  infusion  (BHI) 
medium and got good growth of S. equisimilis H-46A.  
Lee  et  al.  (1997)  achieved  enhanced  production  and 
secretion  of  SK  into  extracellular  medium  by 
Escherichia coli. 
The  increasing  potential  of  SK  application 
promoted  us  to  screen  for  newer  streptokinase-
producing organisms. Also the exponential increase in 
the application of SK in various fields in the last few 
decades  demands  extension  in  both  qualitative 
improvement  and  quantitative  enhancement. 
Quantitative enhancement requires strain improvement 
and medium optimization for the overproduction of the 
enzyme, as the quantities produced by wild strains are 
usually too low. The spectacular success examples of 
strain improvement in industry are mostly attributed to 
the  extensive  application  of  mutation  and  selection. 
Hence,  in  the  present  work,  an  attempt  was  made  to 
isolate streptokinase-producing bacteria and subjecting 
it to strain improvement by random mutagenesis (UV Am. J. Immunol. 1 (4): 125-129, 2005 
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irradiation  and  NTG  (N-methyl-  N’-nitro-N-nitroso 
guanidine) treatment) to enhance SK productivity. 
 
 
MATERIALS AND METHODS 
 
Screening and Isolation of Producing Streptococci: 
A  total  of  nine  samples  were  collected  in  sterile 
containers for the systematic screening of b-haemolytic 
Streptococci. The samples included blood and biomass 
from infected throat (Table 1). 
The b-haemolytic Streptococci were isolated from 
different  samples  by  plating  on  sheep  blood  agar 
medium. They can easily be distinguished on the plate 
from those of other bacteria as they form a clear zone of 
hydrolysis around the colonies. 
In literature, several  media have been suggested 
for the isolation of b-haemolytic Streptococci such as 
blood  agar  and  sodium  azide  (Cruickshank,  1968); 
crystal  violet blood agar, Todd Hewitt infusion broth 
and  PNF  medium    (Collee  et  al.,  1969).  Pour  plate 
method  has  been  used  in  the  present  work  for  the 
isolation of Streptococci. 
To 45 ml of melted and cooled nutrient agar base 
(Hi-media, India) (55°C), sterile sheep blood was added 
at 10% level. To this, 0.05 ml of each test sample was 
mixed and poured into 6” petridishes and incubated at 
37°C  for  24  h.  The  discrete  colonies  with  clear 
hydrolysis zones were picked up, transferred into blood 
agar  slants  and  incubated  at  37°C  for  24  hr.  The 
microorganisms,  which  formed  clear  zones  after 
incubation,  were  selected.  The  selected  isolates  were 
subjected for extracellular SK production by submerged 
fermentation.  
Morphological  and  taxonomic  characteristics  of 
the  promising  isolated  strain  was  examined  by  by 
Bergey’s Manual of Determinative Bacteriology, 1974, 
Bergey’s  Manual  of  Systematic  Bacteriology,  1992, 
Mackie and McCartney Practical Medical Microbiology 
(Collee  et  al.,  1969),  District  Laboratory  Manual 
Practice in Tropical Countries (Monica, 2000), Medical 
Microbiology  (Cruickshank,  1968)  and  Laboratory 
Manual  on  Fundamental  Principles  of  Bacteriology 
(Salle, 1948).  
Strain Improvement Studies: 
UV Irradiation: Strain improvement for the selected 
parent strain, was done by mutation and selection. The 
wild strain was subjected to UV irradiation. Mutation 
frequency was mentioned to be high when the survival 
rates  were  between  10  and  0.1%.  The  dose  survival 
curve was plotted for selecting the mutants between 10 
and 0.1% rate.  
The spore suspension of wild strain was prepared 
in phosphate buffer (pH 8.0) and four ml quantities of 
the  spore  suspension  were  pipetted  aseptically  into 
sterile  petri  dishes  of  80  mm  diameter  having  a  flat 
bottom. The exposure to UV light was carried out in a 
“Dispensing  –  Cabinet”  fitted  with  TUP  40w 
Germicidal lamp which has about 90% of its radiation 
at  2540-2550  A
0.  The  exposure  was  carried  out  at 
distance  of  20.0  cm  away  from  the  center  of  the 
Germicidal  lamp  (UV  light  source)  with  occasional 
shaking. The exposure times were 0, 2, 4, 6, 8 and 10 
min. Each UV exposed cell suspension was stored in 
dark  overnight  to  avoid  photo  reactivation,  then  was 
serially diluted in phosphate buffer and plated on PDA 
medium. The plates were incubated for 24 hr at 37°C 
and the numbers of colonies in each plate were counted. 
Each colony was assumed to be formed from a single 
cell.  A  total  of  15  colonies  (designated  as  AUV1  to 
AUV15)  were  selected  from  the  plates  showing  less 
than 1% survival rate (6 and 8 min UV exposure time) 
and tested for SK production. Among the selectants, the 
best UV mutant strain was used for further studies. 
 
NTG Treatment: The NTG is considered to be a very 
effective  mutagen (Adelberg et al., 1965 and Cerdia-
Olmedo  and  Hanawalt,  1968).  Its  action  has  been 
attributed  to  its  decomposition  products  (Cerdia-
Olmedo  and  Hanawalt,  1968).  The  best  UV  mutant 
(AUV10)  was  used  for  NTG  treatment.  The  spore 
suspension  was  prepared  in  the  same  manner  as 
described earlier. To a 9 ml of spore suspension, 1 ml 
of  sterile  solution  of  NTG  (3  mg/ml  in  phosphate 
buffer)  was  added.  The  reaction  was  allowed  to 
proceed.  Samples  were  withdrawn  from  the  reaction 
mixture at intervals of 30, 60, 90, 120, 150 and 180 min 
and immediately centrifuged for 10 min at 5000 rpm 
and the supernatant solution was decanted. Cells were 
washed three times with sterile water and resuspended 
in 10 ml of sterile phosphate buffer. The samples were 
serially diluted in the same buffer and plated over PDA 
as mentioned earlier. A total of 15 colonies (designated 
as  NUV1  to  NUV15)  were  selected  from  the  plates 
showing less than 1% survival rate (120 and 150 min 
NTG  treated  spore  suspension)  and  tested  for  SK 
production. 
 
Shake Flask Fermentations: The growth of the isolate 
cultivated on nutrient agar slants was scrapped with 5 
ml of sterile distilled water and transferred into 250 ml 
Erlenmeyer  flask  containing  45  ml  of  production 
medium  (Baewald,  1975)  [(g/L):  glucose,  5.0;  yeast 
autolyzate,  5.0;  KH2PO4,  2.5;  KH2PO4,  2.5; 
MgSO4.7H2O,  0.4;  NaHCO3,  1.0;  CH3COONa.3H2O, 
1.0; FeSO4.7H2O, 0.02 and MnCl2.4H20, 0.02 with pH 
7.5.]  in  250  ml  Erlenmeyer  flask.  The  flasks  were 
incubated at 37°C for 24 hr in a shaker incubator (120 
rpm). The culture broth was then filtered and the clear 
filtrate was used as the crude enzyme source. 
 
SK  Assay:    The  SK  activity  was  determined  using 
modified Holmstrom method (Holmstrom, 1965). One Am. J. Immunol. 1 (4): 125-129, 2005 
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unit  (U)  is  defined  as  quantity  of  enzyme  that  will 
liquefy a standard clot of fibrinogen, plasminogen and 
thrombin  at  pH  7.5  at  37°  C  in  18  h.  All  the 
experiments were conducted in triplicate.  
 
 
RESULTS 
 
About 103 Streptococci (with haemolytic activity) 
in total were isolated from the above 9 samples. The 
distribution  of  Streptococci  in  different  samples  is 
shown in Table 1. The isolates  were pooled together 
and cultures, which appeared identical to the naked eye, 
were eliminated. All the isolates were tested for their b-
haemolytic activity on PNF  selective  medium.  About 
47  b-haemolytic  positive  isolates  were  obtained 
(identical  hydrolysis  zone).  Among  these,  20  isolates 
showed moderate to good haemolytic activity. These 20 
isolates (human source) were selected to study their SK 
activities. Among the 20 active isolates, isolate T3 gave 
highest  SK  activity  (681  U/ml).  As  such,  this  isolate 
(T3)  was  subsequently  selected  for  the  taxonomic 
studies.  
 
Table 1:  Sources  of  samples  (distribution  of  Streptococci  in 
different samples)  
S.No     Sample No.     Source of culture     Disease       No. of isolates 
  
1                HB1  Human blood         Septicaemia            9 
2                HB2  Human blood         Septicaemia            10 
3                HB3  Human blood         Septicaemia            14 
4                HT1   Human throat        Acute tonsillitis       11 
5                HT2  Human throat        Acute tonsillitis       10 
6                HT3   Human throat        Scarlet fever            12 
7                HB4   Human blood        Scarlet fever            13 
8                SB5  Sheep blood          Scarlet fever            11 
9                SB6            Sheep blood          Scarlet fever            13 
    Total                  103 
 
Proper  identification  and  characterization  of 
microorganisms is a very important because it expands 
the  scope  for  exploitation  of  industrially  important 
products. To establish the novelty or otherwise of the 
present isolates with those of reported in the literature, 
the  various  morphological,  cultural  and  biochemical 
characteristics of the isolated organisms were compared 
with  the  descriptions  of  the  numerous  Streptococcus 
species cited in the literature. Also Lancefield grouping 
was carried out. The literature survey includes Bergey's 
Manual  of  Systematic  Bacteriology  (1992),  Bergey's 
Manual of Determinative Bacteriology (1974), Mackie 
and McCartney Practical Medical Microbiology (Collee 
et al., 1969), District Laboratory Practice in Tropical 
Countries  (Monica,  2000),  Medical  Microbiology 
(Cruickshank,  1968)  and  Laboratory  Mannual  on 
Fundamental  Principles  of  Bacteriology  (Salle,  1948) 
Biological and Microbiological abstracts and all other 
relevant journals. 
The  characteristics  of  our  isolate  T3  were 
compared  with  that  of  the  reference  cultures.  The 
reference  cultures  used  are:  H46A  strain,  a  group  C 
Streptococci procured from Dr. Malke, Germany and  
NZ131,  a  group  A  Streptococci  procured  from  Dr. 
Ferretti, Oklahoma University, USA. 
The  cultural  characteristics,  physiological  and 
biochemical properties, sugar fermentation,  growth in 
different media and resistance to various inhibitors are 
shown in Table 2. 
The most important characteristics of the strain T3 
are summarized as follows: The cells are spherical in 
shape,  with  moderately  long  chains  in  liquid  media. 
There are no endospores or pellicle formation in broth 
media. They are non-motile and gram-positive. There 
was  no  growth  at  a  temperature  of  10°  or  45°C,  at 
initial pH 9.6 and heating the cells at 60°C for 30 min. 
Growth  was  not  observed  in  media  containing  0.1% 
methylene blue, 6.5% sodium chloride and 40% bile. 
Good growth was observed in media containing sodium 
azide  or  in  crystal  violet  blood  agar  medium  and 
potassium tellurite. The strain exhibited negative litmus 
milk reduction test. It showed a positive b-haemolysis 
and PNF tests. The minimum inhibitory concentration 
(MIC)  of  the  strain  with  benzyl  penicillin  was 
0.02mg/ml.  The  strain  exhibited  negative  CAMP  test. 
The  isolate  did  not  hydrolyze  gelatin,  hippurate  and 
esculin. It hydrolyzed starch and arginine. It exhibited 
negative  tests  of  pyruvate  fermentation,  Voges-
Proskauer (acetoin production), catalase and hydrogen 
sulphide production. The strain showed methyl red and 
nitrate reduction tests positive. 
The final pH in glucose fermentation was 4.7 and 
no gas  was  formed. The acid formation  was positive 
from salicin, trehalose, cellobiose, glycerol, galactose, 
fructose,  xylose,  mannose,  sucrose,  maltose  and 
glucose. The acid formation was negative from inulin, 
lactose, mannitol, raffinose, ribose, sorbitol, melibiose, 
arabinose, inositol, erythritol, dulcitol, dextrin, adonitol, 
rhamnose, soluble starch and potato starch. 
The wild strain of S. equisimilis T3 was subjected 
to strain improvement programme with a view to obtain 
increased SK production and to achieve greater stability 
of  the  organism.  The  first  method  chosen  was  UV 
irradiation.  
The selected mutants were provided with the code 
number  AUV1  to  AUV15  and  these  mutants  were 
tested for their SK producing capabilities (Table 3). The 
results indicated that among UV mutants, AUV10 was 
found to be the highest SK producer (821 U/ml) and it 
was 120% higher yield over the wild strain (681 U/ml). 
The  mutant,  AUV10  was  selected  for  further  strain 
improvement studies using NTG. 
The selected UV mutant, AUV10 was subjected to 
NTG treatment.  A total of 15 mutants  were selected, 
and they were provided with the code numbers NUV1 
to  NUV15.  These  were  evaluated  for  their  SK 
production  capacities  (Table 3). The  results  indicated 
that  the  mutant  NUV7  was  the  highest  SK  yielding 
strain  (996  U/ml).  Thus  the  NTG  treatment  results  a 
mutant that produced 146% higher yield of SK over the  
wild strain (681 U/ml), which is a significant increase 
of yield.  
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Table 2:  Morphological, metabolic, biochemical and sugar fermentation tests of the isolate T3 and reference cultures 
_____________________________________________________________________________________________________________________ 
Morphological and metabolic tests      T3         H46A      NZ 131        Group G      Sugar fermentation tests     T3      H46A        NZ 131    Group G 
Haemolysis               +             +                +                  +            Inulin                              -            -                 -                     + 
PNF test               +             +                +                  +            Lactose                                 -            +                +                     + 
Shape of the cells               S             S                S                  O           Mannitol                               -            -                 -                      -  
Endospores               -              -                 -                   -           Raffinose                              -            -                 -                      -  
Motility               -              -                 -                   -           Ribose                             -            +                 -                     +  
Gram-staining               +             +                +                  +           Salicin                             +           +                +                      -  
Growth at                                                                                                                  Sorbitol                                 -            -                 -                      - 
10°C               -              -                 -                   -            Trehalose                             +            +                +                    +  
45°C                                                      -              -                 -                   -             Cellobiose                           +            +                +                     -  
pH 9.6                                                    -              -                -                   -             Melibiose                             -             -                 -                      -  
Heat tolerance at 60°C for 30 min        -              -                 -                   -             Glycerol                              +            +                 -                     + 
Growth in media containing                                                                                     Arabinose                             -             -                 -                   No 
Methylene blue (0.1% in milk)             -              -                 -                   -             Inositol                                 -            -                 -                    -  
Sodium chloride (6.5%)                        -              -                 -                   -            Galactose                             +            +                +                   No 
Bile salt (40%)                                      -              -                 -                   -            Erythritol                              -             -                 -                   No  
Potassium tellurite                                +             +                +                  +            Dulcitol                                -             -                 -                   No  
Growth in                                                                                                                 Dextrin                                  -             -                +                   No  
Sodium azide medium                          G            M               G                 No         Adonitol                                -             -                 -                   No  
Crystal violet blood agar                      G            M               G                 No         Rhamnose                              -             -                 -                   No  
Litmus milk reduction test                    -              -                 -                  -             Soluble starch                       -             -                 -                   No  
MIC (penicillin G, mg/ml)                  0.02         0.04            0.006    0.004-0.006  Potato starch                          -             -                 -                   No  
cAMP test                                             -              -                 -                  -             Fructose                                +            +                +                   No  
                                                                                                                                 Xylose                                   +            +                +                   No                                                               
Biochemical tests:                                                                                                   Mannose                                +            +                +                   No 
Hydrolysis of                                                                                                           Sucrose                                  +            +                +                   + 
Gelatin                                                  -              -                 ±                 -             Maltose                                  +            +                +                   + 
Starch                                                   +             ±                 -                  -            Glucose                                  +            +                +                   + 
Hippurate                                              -              -                 -                  -            Final pH in gluose broth       4.7        4.9              5.5                 No 
Esculin                                                  -             ±                 ±                ±                    
Arginine                                               +             +                 +                +                       
Pyruvate fermentation                          -              -                 -                  -  
Voges-Proskauer                                  -              -                 -                  -  
Methyl red                                           +              +                +                 +       
Hydrogen sulphide                               -              -                 -                  -  
Catalase                                                -              -                 -                  -  
Nitrate reduction                                  +             +                +                 +       
Lancefield grouping                            C             C                A                G 
G: Good growth, M: Moderate growth, No: Not reported, S: Spherical,  O: Oval, +: Positive reaction, -: Negative reaction 
                       
 
 
Table 3:  UV mutants and NTG treated selectants from AUV 10 and 
their SK activity  
UV mutants   SK activity (U/ml)    NTG mutants    SK activity (U/ml)      
   
AUV1                462.0 ± 12.1               NUV1                673.0 ± 7.6 
AUV2                516.0 ± 15.0               NUV2                668.0 ± 6.3 
AUV3                458.0 ± 14.0               NUV3                684.0 ± 6.9 
AUV4                503.0 ± 14.4               NUV4                717.0 ± 6.1 
AUV5                402.0 ± 13.9               NUV5                740.0 ± 7.3 
AUV6                494.0 ± 15.1               NUV6                469.0 ± 5.9 
AUV7                635.0 ± 16.2               NUV7                996.0 ± 8.5 
AUV8                576.0 ± 16.1               NUV8                772.0 ± 9.2 
AUV9                580.0 ± 16.3               NUV9                597.0 ± 6.0 
AUV10              821.0 ± 17.4               NUV10              663.0 ± 7.1 
AUV11              404.0 ± 16.0               NUV11              499.0 ± 6.3 
AUV12              678.0 ± 15.7               NUV12              677.0 ± 7.4 
AUV13              583.0 ± 16.1               NUV13              467.0 ± 5.7 
AUV14              434.0 ± 13.5               NUV14              366.0 ± 3.5 
AUV15              392.0 ± 12.3               NUV15              716.0 ± 3.4 
T3 (Wild strain) 681.0 ± 16.4           
 
 
DISCUSSION 
A total of 103 isolates were obtained from nine 
samples of blood and biomass from infected throat. Of 
them, 20 isolates showed moderate to good SK activity 
and  the  strain  T3,  which  gave  maximum  enzyme 
activity, was selected for detailed taxonomical studies. 
A  detailed  survey  of  the  literature  indicated 
that our isolate T3 belongs to Streptococci group C. The 
data  indicated  that  our  isolate  is  closure  to  S. 
equisimilis. A detailed comparison of our isolate was 
made to establish its novelty or otherwise. The data is 
presented  in  Table  2.  However,  some  significant 
qualitative  and  quantitative  differences  could  be 
noticed.  Our  isolate  T3  differed  from  the  reference 
culture  in  the  following  aspects:  Good  growth  was 
observed for our isolate T3 on sodium azide and crystal 
violet  blood  agar  media  while  moderate  growth  was 
observed for the reference culture on the same media. 
The MIC against benzyl penicillin of our isolate was 
found  to  be  0.02  mg/ml  while  it  was  0.04  mg/ml  for 
reference.  Regarding  the  biochemical  reactions,  our 
isolate has a slight amylolytic activity while reference 
culture  showed  no  amylolytic  activity.  Esculin 
hydrolysis  was  negative  for  our  isolate  while  it  was 
delay activity for reference. Reference culture produced 
acid from lactose and ribose while our isolate did not Am. J. Immunol. 1 (4): 125-129, 2005 
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produce. In view of these significant differences, it is 
proper to consider our isolate T3 is a new variant of S. 
equisimilis. 
The wild strain of S. equisimilis was subjected 
to strain improvement studies. From the results (Table 
3),  it  is  evident  that  UV  and  NTG  were  effective 
mutagenic  agents  for  strain  improvement  of  S. 
equisimilis  T3.  By  employing  these  techniques,  a 
superior mutant (NUV7) with a productivity of 146% 
(681 to 996 U/ml) higher than that of the wild strain 
was obtained.      
 
CONCLUSIONS 
The results revealed that UV and NTG were 
effective mutagenic agents for strain improvement of S. 
equisimilis  T3  for  enhanced  SK  productivity.  It  is 
hoped that the high yielding mutant strain of the isolate 
S.  equisimilis  T3  can  be  exploited  commercially  for 
large  scale  industrial  production  of  SK.    Also  future 
studies  will  test  SK  in  vivo,  and  the  cloning, 
sequencing,  and  expression  of  the  SK  gene  from 
chromosomal  DNA  of  S.  equisimilis  strain  T3  is 
proceeding.  
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